Press Release Source: BioPartnering North America
BioPartnering North America Program to Provide a Comprehensive Guide to all Aspects of BioPartnering
Thursday December 15, 3:51 pm ET
SANTA CRUZ, Calif.--(BUSINESS WIRE)--Dec. 15, 2005--California, Technology Vision Group LLC (TVG) is pleased to announce the program for the 4th Annual BioPartnering North America (BPN: www.techvision.com/bpn) conference which will be held in Vancouver, B.C., Canada, on February 5-7, 2006 as a partnership between TVG, BC Biotech, BioAlberta and BIOTECanada. Following the major success of the 3rd annual conference which took place earlier this year attendees will once again benefit from BPN's innovative and informative program which, will feature 5 BioPartnering Leadership Sessions, 6 Industry Workshops and 76 company presentations. Together these features will highlight current themes in the biotech industry and form a comprehensive guide to conducting biotech business in today's environment. There are well over 300 attendees from Europe, the US and Asia now registered to attend BPN. To take advantage of the early registration rate, available until January 2, 2006, register online now at www.techvision.com/bpn/registration/.
One of the most popular features of the BPN program is the Open House Presentations, which applications are still be accepted for and the BioPartnering Leadership Sessions, where key issues effecting the growth of the life-science industry today are debated by a group of key industrial leaders. This year the first BioPartnering Leadership Session of the conference is entitled, "Deal-making in Biotechnology: A State of the Industry Review" and will outline an assessment of worldwide strategic partnering and M&A activity in 2005 and of the key implications for 2006. The session will be chaired by Mr James D. Watson, Head of Merchant Banking and Managing Director of the U.S. company, Burrill & Company. He commented,
"Attendance at this session will be vital to those involved in the biotech industry, as it will provide a unique overview of where the industry is at present, how the industry has changed over the past year and where the industry is heading in 2006. The Sessions are a very effective way of staying up to date with trends and events through the eyes of leading industry figures."
Other sessions in this series will look at:
- Which Way to an Exit?
- The Burgeoning Influence of India and Japan: Trans-Pacific Deal Trends
- Why Pharma and Biotech Need Each Other Now More Than Ever
- Early Stage Deals: A Pharma Perspective
Another program highlight of BPN is the Industry Workshops which focus on key topics affecting the biotech industry in a highly interactive environment. These workshops have proven very popular in the past as industry leaders are able to address unique and complex issues in great detail with interested delegates. The topics to be covered in 2006 are: Partnering with Japanese Companies; Financial Terms in Partnering Agreements - Going Beyond the Numbers and Using Probability Weighted Product Models to Optimize Corporate Partnering Negotiations; Raising Capital in Canada and the United States; Building Biotech Value in British Columbia....Partnering, Investing, and Actually Making Money in BC; Looking to Start Operations in British Columbia? Tips Regarding Advertising Tax and Employment Law for Biotech and Pharmaceutical Companies; and Co-Development, Co-Promotion, and Profit Sharing Deals -- How to Preserve Some of the Upside, Without Loosing Your Shirt.
Full program details can be viewed at www.techvision.com/bpn/program.
Applications to present are still being accepted. Limited slots remain.
As well as BioPartnering Leadership Sessions, Industry Workshops and state-of- the-art biopartnering facilities, BPN also provides biotech companies with plenty of show case opportunities with 20 Emerging Company presentations and 56 Open House presentations scheduled. Technology Vision Group is still accepting applications to present, which can be submitted online at www.techvision.com/bpn/registration/presenter/apply.php.
Media registration is now available and is complimentary for accredited members of the news media. To register for BPN, or for further information please contact Helena Podd or Valerie Auffray (Helena.podd@citigatdr.co.uk; Valerie.auffray@citigatedr.co.uk) at Citigate Dewe Rogerson.
Conference Sponsors
Angiotech Pharmaceuticals, Inc., AstraZeneca, PricewaterhouseCoopers LLP, Burrill & Company, Cooley Godward LLP, Ferghana Partners Group, Farris, Vaughan, Wills & Murphy LLP, Morrison & Foerster, Bristol-Myers Squibb Company, Merck, Pfizer, QLT Inc., Novartis, Roche, Seed I.P. Law Group PLLC, UK Trade & Investment, Dorsey & Whitney, Forbes Medi-Tech Inc., Genome British Columbia, Gowlings, International Trade Canada, Japan External Trade Organization, International Trade Canada, Life Science Analytics, Inc., Marsh Canada Limited, Quintiles Transnational Corp., UBC University-Industry Liaison Office, Torys LLP
Conference Supporters
Bio Business, BioExecutive, Biotechnology Focus, BioWorld Today, CCNMathews, Citigate Dewe Rogerson, Contact Canada, Global Bioscience Partnership, Red Herring
2006 Emerging Company Presenters
(OSI) Prosidion, AerovectRx Corporation, Antibe Therapeutics Inc., EcoBiotics, iCo Therapeutics Inc., KAI Pharmaceuticals, Nerites Corporation, Nura Inc., OsteoCorp, Predix Pharmaceuticals, Reata Pharmaceuticals, Inc., Replikun Biotech Pty Limited, Vitae Pharmaceuticals, Inc.
2006 Open House Presenters
Alchemia Limited, Allon Therapeutics, Inc., Alphora Research Inc., Antisoma, Avidex Ltd, Biolex Theraputics, BioWa, Inc., Boston Life Sciences, Inc., CANTEST, BioPharma Services, Celator Pharmaceuticals, Cell Signals Inc., Corgentech, Curis, Inc., Cytokinetics, Inc., Engene Inc., Evolutec Group Plc, Forbes Medi-Tech Inc., ImaRx Therapeutics, Inc., Ingenium Pharmaceuticals, Inimex Pharmaceuticals, Inc., InNexus Biotech, Jiangsu Simcere Pharmaceutical R&D Co., Ltd, Liponex Inc., MaxCyte, Inc., Medicago Inc., Meristem Therapeutics, Miltenyi Bioprocess, Novacta Biosystems Ltd, NovaDel Pharma, Nycomed, Oncolytics Biotech Inc., OXFORD BIOMEDICA, Paradigm Therapeutics Ltd, Patheon Inc., Pharmacyclics, Product Safety Labs, Protox Therapeutics Incorporated, PTC Therapeutics, Inc., RNTECH SAS, Santaris Pharma, SemBioSys Genetics, Stem Cell Therapeutics Corp., TopoTarget UK Ltd, Torcan Chemical Ltd., ToxTest, Transition Therapeutics Inc., Urigen, Xantos Biomedicine AG, XOMA Ltd., YM BioSciences Inc.
Contact:
Technology Vision Group LLC
Nancy Connelly (Director)
Delegates Contact
(831) 464-4230 ext. 110
neconnelly@techvision.com
www.techvision.com/bpn
OR
Oxford Biomed stock quotes
Oxford Biomed stock charts
Follow this thread
